Skip to content

E-Cigarette Effects on Markers of Cardiovascular and Pulmonary Disease

E-Cigarette Effects on Markers of Cardiovascular and Pulmonary Disease Risk (Aka CLUES - Cardiac and Lung E-cig Smoking Study)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03863509
Enrollment
450
Registered
2019-03-05
Start date
2019-03-05
Completion date
2022-03-09
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, E-Cigarette Use, Pulmonary Disease, Tobacco Use

Keywords

vape, E-Cigarette, E-cig

Brief summary

This study is designed to enhance the understanding of the possible health effects of e-cigarette use by relating the acute and long-term use of e-cigarettes and conventional cigarettes (products) to well-validated cardiovascular and pulmonary disease biomarkers. Participants will be enrolled in 3 groups: exclusive e-cigarette users, exclusive cigarette smokers, and a control group of never-users. Participants can expect up to 4 weeks of study participation.

Detailed description

E-cigarette use is increasing rapidly in the United States, especially amongst youth, underscoring the vital need to improve understanding of its health risks. Relevant data could inform policy, guide public health and clinical intervention efforts, and inform individuals who might use or who are using this product. This research will significantly enhance the understanding of the possible health effects of e-cigarette use by relating the acute and long-term use of e-cigarettes and conventional cigarettes (products) to well-validated cardiovascular and pulmonary disease biomarkers. 3 different use-groups of participants will be enrolled: exclusive e-cigarette users (n=165), exclusive cigarette smokers (n=165), and a control group of never-users (n=110). These groups reflect the primary decisions that people can make regarding their future tobacco use: to continue to smoke cigarettes, to switch to e-cigarettes, or to avoid tobacco use entirely. It is essential that smokers and health care providers have accurate information on the health effect of these choices. \[Additionally, 100 participants will be invited to be part of an epigenetics sub-study (50 E-cig users, 25 smokers and 25 controls), prior to smoking, an additional 16 ml of blood will be collected in Vacutainer cell separation tubes for peripheral blood monocyte (PBMC) Isolation containing sodium citrate.\] Product use will be related to well-validated biomarkers that sensitively and reproducibly reflect mechanisms, injury, and/or future risk related to cardiovascular or pulmonary disease. Biomarkers will be related to: 1) acute product use in the laboratory (exposure challenges), 2) lifetime history of product use, and/or 3) real-time measures of product use in participants' daily lives. The primary cardiovascular biomarkers are brachial artery flow-mediated dilation (a measure of endothelial function) and carotid intima-media thickness, a measure of subclinical arterial injury and atherosclerosis. The primary pulmonary disease biomarkers will be measures of lung volumes and flow rates (Forced Expiatory Volume exhaled in the first second (FEV1), Forced vital capacity (FVC), FEV1/FVC) obtained by spirometry. Treadmill exercise stress testing will be performed (to assess aerobic fitness), electrocardiography (to measure heart rate variability, HRV), and measure heart rate, blood pressure, lipids, HgbA1c, and inflammation/oxidation markers (leukocyte count, C-reactive protein, urinary F2 isoprostanes and exhaled nitric oxide). This research will show how product use-groups differ in response to acute product use and long-term use as they are related to key cardiovascular and pulmonary biomarkers. Objective measures of product use include exhaled CO and plasma nicotine/cotinine and urinary nicotine/cotinine concentrations. History of product use within use-groups will be related to biomarker status. The proposed research will yield vital and comprehensive data regarding product use, subclinical arterial injury, atherosclerosis burden, arterial and pulmonary function, cardiac and aerobic fitness, cardiac autonomic regulation, systemic and pulmonary inflammation, and oxidative stress, as well as other key outcomes. These data will serve as a foundation for future longitudinal investigations of e-cigarette health effects and will inform public policy decisions, clinical intervention, and patient guidance regarding e-cigarettes.

Interventions

BEHAVIORALCigarettes

smokes daily

BEHAVIORALE-Cigarettes

E-cigarette usage \>/= 5 days/week

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* able to read and write English * no plans to quit smoking and/or e-cig use in the next month * not using cigars/smokeless/snus tobacco \>/= 1 time per week * having a stable pattern of current product use * able to walk at least 2 blocks without assistance or stopping * Specific to Exclusive Smokers: * smokes daily * \>/= 5 cigs/day for last 6 months * \< 3 uses E-cigs in lifetime * \>/= 5 ppm carbon monoxide (CO) * Cotinine \> 100 ng/ml * Specific to Exclusive E-cig users: * \</= 2 days per month cigarette use for last 6 months * \>/= 5 days per week E-cig use for last 3 months * \</= 4 ppm CO * Cotinine \> 100 ng/ml * Specific to Never-users * \< 100 cigarettes in a lifetime, none for \> 5 years * \< 3 E-cig uses in a lifetime * \</= 4 ppm CO * Cotinine \< 100 ng/ml

Exclusion criteria

* current use of a smoking cessation medication * women who are pregnant or plan to get pregnant in the coming month * women who might be pregnant * incarcerated individuals * history of sarcoidosis in past 5 years, or active interstitial lung/pulmonary fibrosis * history of positive Coronavirus-19 test

Design outcomes

Primary

MeasureTime frameDescription
Changes in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challengebefore and after less than 15 minutes from smoking/ vaping product (up to 4 weeks from enrollment)Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge FeNO was obtained sitting and repeated within 15 minutes after smoking/vaping challenge.
Changes in Systolic Blood Pressure Pre- and Post-challenge.During Visit 2 (1 - 4 weeks post enrollment) before and after smoking/vaping challenge and for controls after a 10 minute breakVisit 2 was scheduled up to 4 weeks from enrollment visit, fasting.. They came in the morning after 8 hours of fasting and refraining from nicotine products. Systolic blood pressure (left brachial artery using an oscillometric method) was measured supine, after 10 minutes rest (Pre) and repeated after they underwent smoking or vaping changes. The post challenge blood pressures were recorded 15-20 minutes post end of exposure. For controls, all measurements were repeated in the same order after a 10 minute break.
Changes in Diastolic Blood Pressure Pre- and Post-challenge.before and after smoking/vaping challenge during Visit 2 (up to 4 weeks from enrollment)Participants returned for V2 up to 4 weeks from enrollment visit, fasting. They came in the morning after 8 hours of fasting and refraining from nicotine products. Diastolic blood pressure (left brachial artery using an oscillometric method) was measured supine, after 10 minutes rest (Pre) and repeated after they underwent smoking or vaping changes. The post challenge blood pressures were recorded 15-20 minutes post end of exposure. For controls, all measurements were repeated in the same order after a 10 minute break.
Changes in Heart Rate Pre- and Post-challenge.Before and after smoking/vaping challenge during Visit 2 (up to 4 weeks from enrollment)Visit 2 was scheduled up to 4 weeks from enrollment visit, fasting. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge heart rate measured supine, after 10 minutes rest from blood pressure monitor (dinamap). The post challenge heart rates were recorded 15-20 minutes post end of exposure to smoking or vaping challenge completion or in the case of controls after a 10 minute break.
Changes in Brachial Artery Diameter Pre- and Post-challengebefore and after smoking/vaping challenge during Visit 2 (up to 4 weeks from enrollment)Visit 2 was scheduled up to 4 weeks from enrollment visit. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge brachial artery diameter imaged with ultrasound after resting supine for 10 minutes before and repeated 15-20 minutes after smoking/vaping challenge ended. or in the case of controls after a 10 minute break.
Changes in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challengeTesting was done after 10 minutes rest and fasting for pre- and post-challenge. The post challenge FMD were recorded 15-20 minuted after end of exposure (up to 4 weeks from enrollment)Visit 2 was scheduled up to 4 weeks from enrollment visit. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge ultrasound of brachial artery diameter imaged with ultrasound after resting supine for 10 minutes before and repeated 15-20 minutes after smoking/vaping challenge ended. or in the case of controls after a 10 minute break. The FMD protocol includes measuring % change in resting diameter after 60-90 seconds post fore-arm cuff occlusion release.
Changes in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challengeDuring V2 (scheduled up to 4 weeks from enrollment) and obtained after 10 minutes of supine rest, before and after smoking/vaping challengeExpressed as a percentage of beats (supine recordings had be 5 minutes or longer to be valid). We used the SphygmoCor system for these recordings (Atcor medical). Participants attended V2 1-2 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability was recorded supine for 10 minutes or more, pre and post smoking/vaping challenge. For controls is was repeated after a 10-minute break.
Changes in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challengeheart rate variability recordings of at least 10 minutes per-challenge and 15 minutes post-challenge (up to 4 weeks from enrollment)Participants attended V2 up to 4 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability was recorded supine for 10 minutes or more, pre and post smoking/vaping challenge. For controls it was repeated after a 10 minute break.
Changes in Heart Rate Variability Standing Ratio Pre- and PostchallengeRatio was measured pre- and post- smoking/vaping challenge after completion of the 10 minutes of heart rate variability measures (up to 4 weeks from enrollment)We used the SphygmoCor system for these recordings (Atcor medical). Participants attended V2 up to 4 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability standing ratio was assessed pre and post smoking/vaping challenge. For controls is was repeated after a 10-minute break. Ratio between maximal heart rate after abrupt standing from a supine position and the subsequent lowest heart rate value within 40 seconds of peak.
Changes in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challengebefore and after smoking/vaping challenge during Visit 2 (1-4 weeks after enrollment visit)maximum amount of air that the subject can forcibly expel during the first second following maximal inhalation, expressed as a percentage of the predicted normal values in the population. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.
Changes in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge.before and after smoking/vaping challenge during Visit 2 Visit 2 which was scheduled 1 to 4 weeks from enrollment visit, fastingAmount of air that can be forcibly exhaled after taking the deepest breath possible expressed as a predicted percentage from the normal population. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.
Changes in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challengebefore and after smoking/vaping challenge during Visit 2 (1-4 weeks after enrollment visit)The post challenge spirometry was recorded \<15 minutes post end of exposure. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.
Changes in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challengeSpirometry performed pre-challenge and within 15 minutes post-challenge (up to 4 weeks from enrollment)Participants attended Visit 2 (1-4 weeks after enrollment visit). They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.
Brachial Artery Flow-Mediated Dilation (FMD)- Pre ChallengeV2 up to 4 weeks from enrollment visit, fastingBrachial Artery Flow-Mediated Dilation is a primary cardiovascular biomarker and a measure of endothelial function that will be assessed before and after an acute exposure challenge. These are pre-challenge values. Ultrasound based changes in brachial artery diameter after a forearm cuff occlusion (250mmHg) for 5 minutes. FMD is the percent change in brachial diameter measured 60 to 90 seconds post cuff release compared to its resting diameter. A higher % dilation is an indication of better endothelial function.
Forced Expiratory Volume (FEV1)- Pre ChallengeV2 up to 4 weeks from enrollment visit , fasting, pre challenge sessionFEV1 is a primary measure of pulmonary disease obtained by spirometry that will be assessed before and after an acute exposure challenge. These are per-challenge values
Carotid Intima-Media Thickness (IMT)V2 up to 4 weeks from enrollment visit, only done pre-challengeCarotid Intima-Media Thickness is a cardiovascular biomarker and a measure of sub-clinical arterial injury and atherosclerosis as a result of chronic exposure. IMT will be measured via ultrasonography.

Secondary

MeasureTime frameDescription
Heart Rate Variability (HRV) - Pre Product Use ChallengeV2 two was generally scheduled 1-4 weeks after enrollment visit with a window up to 4 weeks. HRV measures obtained after resting supine for 10 minutesHeart Rate Variability PNN50(%) measured before an exposure challenge. Participants attended visit 2 fasting and refraining from nicotine for at least 8 hours.
Systolic Blood Pressure (BP)V2 was up to 4 weeks from enrollment visit, after resting supine for 10 minutesBlood Pressure measured using the oscillometric technique before an acute exposure challenge following standardized protocol. After resting supine for 10 minutes blood pressure was measured on both arms and the average of the last two values was used.
Forced Vital Capacity (FVC)recordings obtained during V2 in the morning, fasting and refraining from nicotine for at least 8 hours. This visit was generally 1-2 weeks after enrollment date with a window up to 4 weeksForced Vital Capacity is a measure of how much air can be exhaled forcefully obtained by spirometry pre acute exposure challenge.
Fractional Exhaled Nitric Oxide (FeNO)recordings obtained during V2 in the morning, fasting and refraining from nicotine for at least 8 hours. This visit was generally 1-2 weeks after enrollment date with a window up to 4 weeksFractional Exhaled Nitric Oxide is a measure of airway inflammation measured before an acute exposure challenge.
Autonomic Measures - RMSSDv2 was generally 1-2 weeks after enrollment visit, with a window up to 4 weeks from V1Root mean square of standard deviation of rr intervals. Obtained fasting and refraining from nicotine exposure using the Sphymocor system. We used 10 or more minutes of supine data to derive heart rate variability measures.
Arterial Pulse Wave Analysis (PWA), Augmentation Index (at 75 Bpm, %)v2 was generally 1-2 weeks after enrollment visit, with a window up to 4 weeks from V1Analysis of radial pressure wave forms allows for non-invasive estimation of central aortic pressures, accounting for pressure amplification and the amplitude of the arterial pulse wave as it moves through arteries away from the heart. The Atcor Sphygmacor system can derive central aortic pressures from radial tracings using a validated transfer function. This computation is performed using the pulse wave analysis (PWA) mode. Pulse Wave Analysis via radial tonometry was obtained as a measure of chronic exposure.
Exercise Treadmill Stress Test (ETT)-Peak METSTreadmill test done only once at the end of v2 after completion of all other post-challenge assessment tests. V2 was scheduled 1-4 weeks from enrollment vistAn ETT to determine exercise capacity will be completed as a measure of chronic exposure. Peak metabolic equivalents (METs, 1 MET=3.5 ml O2 uptake/kg body weight/minute) were determined at all exercise stages, peak exercise, and 1-minute post-exercise.
Diastolic Blood Pressure (DBP)V2 was generally 1-2 weeks after enrollment with a window up to 4 weeks from V1, recorded after resting supine for 10 minutesDuring V2, Diastolic Blood Pressure was measured using the oscillometric technique before an acute exposure challenge following a standardized protocol. After resting supine for 10 minutes blood pressure was measured on both arms and the average of the last two values was used. Participants attended v2 in the morning, fasting and refraining from nicotine products for at least 8 hours.
Peak Rate Pressure Product (RPP, Peak Heart Rate Multiplied by Peak Systolic Blood Pressure)During V2 (1-4 weeks after enrollment visit) the treadmill stress test was done last, following Nicotine-containing product challenge (users) or pretend 10 minute exposure for controlsPeak RPP was calculated by multiplying maximun heart rate during exercise by systolic blood pressure as a reliable assessment of cardiac workload
Heart Rate Reserve (%)During V2 (1-4 weeks after enrollment visit) the treadmill stress test was done last, following Nicotine-containing product challenge (users) or 10 minute pretend exposure for never-usersMeasure of maximal exercise capacity adjusted for age, calculated as max heart rate during treadmill divided by (220 minus the participant's age in yrs)
60 Seconds Heart Rate Recovery (Beats Per Minute)During V2 (1-4 weeks after enrollment visit) the treadmill stress test was done last, following Nicotine-containing product challenge (users) or pretend 10 minute exposure for controlsDifference in heart rate 60 seconds post treadmill minus maximal heart rate during treadmill..
Heart Rate (HR)Participants attended V2 generally 1-4 weeks after enrollment with a window that allowed up to 4 weeks after enrollmentHeart Rate pre-acute exposure challenge was obtained after resting supine for 10 minutes during V2 in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior.

Countries

United States

Participant flow

Recruitment details

March 5 2019 started enrollment, ended last visit March 9th 2022. Studies were conducted at the University of Wisconsin Hospital and Clinics and the Center for Tobacco Research and Intervention (CTRI) in Madison, WI and for a short period we also at CTRI location in Milwaukee,WI.

Pre-assignment details

Participants tested for Exhaled CO and urinary nicotine to determine if they qualified for either arm of the study. E-cigarette vapers exclusively (exhaled CO less than 5 ppm and nicotine in urine), cigarettes exclusively (CO more or equal 5 ppm, positive urine nicotine), and controls (CO less than 5 ppm, and negative nicotine in urine). NOTE: one participant was enrolled twice completing all study visits. Later, when this was noticed, we amended procedures, only his initial data was used.

Participants by arm

ArmCount
Exclusive Smokers
Smokes Daily; \>/= 5 cigarettes/day for last 6 months Cigarettes: smokes daily
117
Exclusive E-Cig Users
E-cig usage \>/= 5 days/week for last 3 months E-Cigarettes: E-cigarette usage \>/= 5 days/week
164
Never Users
\< 100 cigarettes in lifetime, none for \> 5 years; \< 3 E-cig usage in lifetime
114
Total395

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyCOVID-19 shutdown period040
Overall StudyDid not qualify due to comorbidities, positive COVID-9, high CO, Low CO, Negative nicotine in urine10202
Overall StudyLost to Follow-up802
Overall StudyMissed V2 visit- outside protocol window431
Overall StudyWhile cleaning datasets, we realized one participant was enrolled twice.010

Baseline characteristics

CharacteristicTotalNever UsersExclusive E-Cig UsersExclusive Smokers
Age, Continuous32.9 years
STANDARD_DEVIATION 13.6
30.8 years
STANDARD_DEVIATION 11.9
27.4 years
STANDARD_DEVIATION 10.6
42.8 years
STANDARD_DEVIATION 13.8
Ethnicity (NIH/OMB)
Hispanic or Latino
12 Participants6 Participants5 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
382 Participants108 Participants159 Participants115 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants0 Participants0 Participants1 Participants
Exhaled CO6.8 ppm
STANDARD_DEVIATION 9.7
2.79 ppm
STANDARD_DEVIATION 1.73
2.96 ppm
STANDARD_DEVIATION 1.89
16.11 ppm
STANDARD_DEVIATION 13.7
Race (NIH/OMB)
American Indian or Alaska Native
2 Participants0 Participants1 Participants1 Participants
Race (NIH/OMB)
Asian
37 Participants21 Participants9 Participants7 Participants
Race (NIH/OMB)
Black or African American
47 Participants5 Participants4 Participants38 Participants
Race (NIH/OMB)
More than one race
23 Participants9 Participants9 Participants5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants0 Participants0 Participants1 Participants
Race (NIH/OMB)
White
285 Participants79 Participants141 Participants65 Participants
Region of Enrollment
United States
395 participants114 participants164 participants117 participants
Serum Cotinine (ng/ml)140.4 ng/ml
STANDARD_DEVIATION 141
2.99 ng/ml
STANDARD_DEVIATION 8.88
193.5 ng/ml
STANDARD_DEVIATION 111.7
231.3 ng/ml
STANDARD_DEVIATION 127.7
Serum Nicotine (ng/ml)3.07 ng/ml
STANDARD_DEVIATION 3.07
1.99 ng/ml
STANDARD_DEVIATION 0
2.95 ng/ml
STANDARD_DEVIATION 2.58
4.48 ng/ml
STANDARD_DEVIATION 4.54
Sex: Female, Male
Female
173 Participants57 Participants64 Participants52 Participants
Sex: Female, Male
Male
222 Participants57 Participants100 Participants65 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 1170 / 1640 / 114
other
Total, other adverse events
0 / 1171 / 1641 / 114
serious
Total, serious adverse events
0 / 1170 / 1640 / 114

Outcome results

Primary

Brachial Artery Flow-Mediated Dilation (FMD)- Pre Challenge

Brachial Artery Flow-Mediated Dilation is a primary cardiovascular biomarker and a measure of endothelial function that will be assessed before and after an acute exposure challenge. These are pre-challenge values. Ultrasound based changes in brachial artery diameter after a forearm cuff occlusion (250mmHg) for 5 minutes. FMD is the percent change in brachial diameter measured 60 to 90 seconds post cuff release compared to its resting diameter. A higher % dilation is an indication of better endothelial function.

Time frame: V2 up to 4 weeks from enrollment visit, fasting

Population: % FMD pre-challenge after 8 hours refraining from nicotine exposure. A higher % dilation is an indication of better endothelial function.

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersBrachial Artery Flow-Mediated Dilation (FMD)- Pre Challenge4.25 Percent change from resting diameterStandard Deviation 3.17
Exclusive E-Cig UsersBrachial Artery Flow-Mediated Dilation (FMD)- Pre Challenge4.89 Percent change from resting diameterStandard Deviation 2.92
Never UsersBrachial Artery Flow-Mediated Dilation (FMD)- Pre Challenge5.31 Percent change from resting diameterStandard Deviation 3.43
p-value: 0.494ANCOVA
Primary

Carotid Intima-Media Thickness (IMT)

Carotid Intima-Media Thickness is a cardiovascular biomarker and a measure of sub-clinical arterial injury and atherosclerosis as a result of chronic exposure. IMT will be measured via ultrasonography.

Time frame: V2 up to 4 weeks from enrollment visit, only done pre-challenge

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersCarotid Intima-Media Thickness (IMT)0.67 mmStandard Deviation 0.18
Exclusive E-Cig UsersCarotid Intima-Media Thickness (IMT)0.54 mmStandard Deviation 0.1
Never UsersCarotid Intima-Media Thickness (IMT)0.54 mmStandard Deviation 0.1
p-value: 0.074ANCOVA
Primary

Changes in Brachial Artery Diameter Pre- and Post-challenge

Visit 2 was scheduled up to 4 weeks from enrollment visit. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge brachial artery diameter imaged with ultrasound after resting supine for 10 minutes before and repeated 15-20 minutes after smoking/vaping challenge ended. or in the case of controls after a 10 minute break.

Time frame: before and after smoking/vaping challenge during Visit 2 (up to 4 weeks from enrollment)

Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw.

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersChanges in Brachial Artery Diameter Pre- and Post-challenge0.378 centimeters (cm)Standard Deviation 0.062
Exclusive E-Cig UsersChanges in Brachial Artery Diameter Pre- and Post-challenge0.370 centimeters (cm)Standard Deviation 0.063
Never UsersChanges in Brachial Artery Diameter Pre- and Post-challenge0.388 centimeters (cm)Standard Deviation 0.064
Exclusive E-cigarette Users Post-challengeChanges in Brachial Artery Diameter Pre- and Post-challenge0.378 centimeters (cm)Standard Deviation 0.063
Exclusive Smokers Pre-challengeChanges in Brachial Artery Diameter Pre- and Post-challenge0.410 centimeters (cm)Standard Deviation 73
Exclusive Smokers After Smoking ChallengeChanges in Brachial Artery Diameter Pre- and Post-challenge0.398 centimeters (cm)Standard Deviation 0.068
Comparison: Linear mixed models adjusted for age, sex, race/ethnicity compared the within-and between-group responses following product use.p-value: 0.002Mixed Models Analysis
Comparison: Fixed effects from mixed models of measures before and after nicotine-containing product challenge (covariate-adjusted)p-value: 0.00395% CI: [-0.01, -0.002]Mixed Models Analysis
p-value: 0.00195% CI: [-0.01, -0.002]Mixed Models Analysis
p-value: 0.582Mixed Models Analysis
Primary

Changes in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challenge

Visit 2 was scheduled up to 4 weeks from enrollment visit. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge ultrasound of brachial artery diameter imaged with ultrasound after resting supine for 10 minutes before and repeated 15-20 minutes after smoking/vaping challenge ended. or in the case of controls after a 10 minute break. The FMD protocol includes measuring % change in resting diameter after 60-90 seconds post fore-arm cuff occlusion release.

Time frame: Testing was done after 10 minutes rest and fasting for pre- and post-challenge. The post challenge FMD were recorded 15-20 minuted after end of exposure (up to 4 weeks from enrollment)

Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw.

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersChanges in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challenge5.31 percent changeStandard Deviation 3.43
Exclusive E-Cig UsersChanges in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challenge4.22 percent changeStandard Deviation 3.01
Never UsersChanges in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challenge4.89 percent changeStandard Deviation 2.92
Exclusive E-cigarette Users Post-challengeChanges in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challenge4.62 percent changeStandard Deviation 3.52
Exclusive Smokers Pre-challengeChanges in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challenge4.25 percent changeStandard Deviation 3.17
Exclusive Smokers After Smoking ChallengeChanges in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challenge3.57 percent changeStandard Deviation 2.26
Comparison: Linear mixed models adjusted for age, sex, race/ethnicity compared the within-and between-group responses following product usep-value: 0.175Mixed Models Analysis
Comparison: Fixed effects from mixed models of measures before and after nicotine-containing product challenge (covariate-adjusted)p-value: 0.06795% CI: [-0.05, 1.56]Mixed Models Analysis
p-value: 0.46495% CI: [-0.55, 1.2]Mixed Models Analysis
p-value: 0.284Mixed Models Analysis
Primary

Changes in Diastolic Blood Pressure Pre- and Post-challenge.

Participants returned for V2 up to 4 weeks from enrollment visit, fasting. They came in the morning after 8 hours of fasting and refraining from nicotine products. Diastolic blood pressure (left brachial artery using an oscillometric method) was measured supine, after 10 minutes rest (Pre) and repeated after they underwent smoking or vaping changes. The post challenge blood pressures were recorded 15-20 minutes post end of exposure. For controls, all measurements were repeated in the same order after a 10 minute break.

Time frame: before and after smoking/vaping challenge during Visit 2 (up to 4 weeks from enrollment)

Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw.

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersChanges in Diastolic Blood Pressure Pre- and Post-challenge.70.40 mmHgStandard Deviation 7.13
Exclusive E-Cig UsersChanges in Diastolic Blood Pressure Pre- and Post-challenge.72.51 mmHgStandard Deviation 7.73
Never UsersChanges in Diastolic Blood Pressure Pre- and Post-challenge.71.12 mmHgStandard Deviation 7.52
Exclusive E-cigarette Users Post-challengeChanges in Diastolic Blood Pressure Pre- and Post-challenge.75.31 mmHgStandard Deviation 8.54
Exclusive Smokers Pre-challengeChanges in Diastolic Blood Pressure Pre- and Post-challenge.76.64 mmHgStandard Deviation 10.72
Exclusive Smokers After Smoking ChallengeChanges in Diastolic Blood Pressure Pre- and Post-challenge.81.04 mmHgStandard Deviation 10.78
Comparison: Linear mixed models adjusted for age, sex, race/ethnicity compared the within-and between-group responses following product usep-value: 0.003Mixed Models Analysis
Comparison: Fixed effects from mixed models of measures before and after nicotine-containing product challenge (covariate-adjusted)p-value: 0.00295% CI: [0.01, 0.05]Mixed Models Analysis
Comparison: Fixed effects from mixed models of measures before and after nicotine-containing product challenge (covariate-adjusted)p-value: 0.00395% CI: [0.01, 0.05]Mixed Models Analysis
Comparison: Fixed effects from mixed models of measures before and after nicotine-containing product challenge (covariate-adjusted)p-value: 0.917Mixed Models Analysis
Primary

Changes in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge.

Amount of air that can be forcibly exhaled after taking the deepest breath possible expressed as a predicted percentage from the normal population. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.

Time frame: before and after smoking/vaping challenge during Visit 2 Visit 2 which was scheduled 1 to 4 weeks from enrollment visit, fasting

Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw. Some spirometry recordings were of poor quality and upon review by pulmonologist they were deemed not usable.

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersChanges in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge.96.45 predicted percentileStandard Deviation 15.06
Exclusive E-Cig UsersChanges in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge.95.00 predicted percentileStandard Deviation 14.19
Never UsersChanges in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge.98.25 predicted percentileStandard Deviation 13.5
Exclusive E-cigarette Users Post-challengeChanges in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge.96.77 predicted percentileStandard Deviation 15.79
Exclusive Smokers Pre-challengeChanges in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge.90.28 predicted percentileStandard Deviation 15.99
Exclusive Smokers After Smoking ChallengeChanges in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge.87.88 predicted percentileStandard Deviation 16.55
Comparison: Linear mixed models adjusted for age, sex, race/ethnicity compared the within-and between-group responses following product use.p-value: 0.771Mixed Models Analysis
Comparison: Fixed effects from mixed models of measures before and after nicotine-containing product challenge (covariate-adjusted)p-value: 0.91895% CI: [-2.35, 2.12]Mixed Models Analysis
p-value: 0.51895% CI: [-3.22, 1.63]Mixed Models Analysis
p-value: 0.539Mixed Models Analysis
Primary

Changes in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challenge

Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge FeNO was obtained sitting and repeated within 15 minutes after smoking/vaping challenge.

Time frame: before and after less than 15 minutes from smoking/ vaping product (up to 4 weeks from enrollment)

Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw. Other missing records were due to equipment malfunction or participant not being able to follow instructions to complete the test correctly.

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersChanges in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challenge16.17 parts per billion (ppb)Standard Deviation 11.04
Exclusive E-Cig UsersChanges in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challenge16.97 parts per billion (ppb)Standard Deviation 12.52
Never UsersChanges in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challenge14.51 parts per billion (ppb)Standard Deviation 14.71
Exclusive E-cigarette Users Post-challengeChanges in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challenge13.64 parts per billion (ppb)Standard Deviation 14.47
Exclusive Smokers Pre-challengeChanges in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challenge9.67 parts per billion (ppb)Standard Deviation 12.26
Exclusive Smokers After Smoking ChallengeChanges in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challenge9.93 parts per billion (ppb)Standard Deviation 11.84
Comparison: Linear mixed models adjusted for age, sex, race/ethnicity compared the within-and-between-group responses following product use Outcome measure ln transformed for analysis.p-value: 0.001Mixed Models Analysis
Comparison: Fixed effects from mixed models of measures before and after nicotine-containing product challenge (covariate-adjusted)p-value: 0.00195% CI: [-0.14, -0.04]Mixed Models Analysis
p-value: 0.55595% CI: [-0.08, 0.04]Mixed Models Analysis
p-value: 0.007Mixed Models Analysis
Primary

Changes in Heart Rate Pre- and Post-challenge.

Visit 2 was scheduled up to 4 weeks from enrollment visit, fasting. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge heart rate measured supine, after 10 minutes rest from blood pressure monitor (dinamap). The post challenge heart rates were recorded 15-20 minutes post end of exposure to smoking or vaping challenge completion or in the case of controls after a 10 minute break.

Time frame: Before and after smoking/vaping challenge during Visit 2 (up to 4 weeks from enrollment)

Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw.

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersChanges in Heart Rate Pre- and Post-challenge.59.57 beats per minute (bpm)Standard Deviation 8.19
Exclusive E-Cig UsersChanges in Heart Rate Pre- and Post-challenge.58.42 beats per minute (bpm)Standard Deviation 7.88
Never UsersChanges in Heart Rate Pre- and Post-challenge.58.34 beats per minute (bpm)Standard Deviation 9.22
Exclusive E-cigarette Users Post-challengeChanges in Heart Rate Pre- and Post-challenge.63.17 beats per minute (bpm)Standard Deviation 10.13
Exclusive Smokers Pre-challengeChanges in Heart Rate Pre- and Post-challenge.65.31 beats per minute (bpm)Standard Deviation 11.65
Exclusive Smokers After Smoking ChallengeChanges in Heart Rate Pre- and Post-challenge.69.15 beats per minute (bpm)Standard Deviation 12.05
Comparison: Linear mixed models adjusted for age, sex, race/ethnicity compared the within-and between-group responses following product usep-value: <0.001Mixed Models Analysis
Comparison: Fixed effects from mixed models of measures before and after nicotine-containing product challenge (covariate-adjusted)p-value: <0.00195% CI: [4.83, 7.3]Mixed Models Analysis
p-value: <0.00195% CI: [3.76, 6.42]Mixed Models Analysis
p-value: 0.107Mixed Models Analysis
Primary

Changes in Heart Rate Variability Standing Ratio Pre- and Postchallenge

We used the SphygmoCor system for these recordings (Atcor medical). Participants attended V2 up to 4 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability standing ratio was assessed pre and post smoking/vaping challenge. For controls is was repeated after a 10-minute break. Ratio between maximal heart rate after abrupt standing from a supine position and the subsequent lowest heart rate value within 40 seconds of peak.

Time frame: Ratio was measured pre- and post- smoking/vaping challenge after completion of the 10 minutes of heart rate variability measures (up to 4 weeks from enrollment)

Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw. Some participants pre or post challenge due to poor ECG signals (noise) or frequent premature ventricular contractions did not have a usable recording

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersChanges in Heart Rate Variability Standing Ratio Pre- and Postchallenge1.57 ratio (unitless)Standard Deviation 0.26
Exclusive E-Cig UsersChanges in Heart Rate Variability Standing Ratio Pre- and Postchallenge1.55 ratio (unitless)Standard Deviation 0.22
Never UsersChanges in Heart Rate Variability Standing Ratio Pre- and Postchallenge1.55 ratio (unitless)Standard Deviation 0.23
Exclusive E-cigarette Users Post-challengeChanges in Heart Rate Variability Standing Ratio Pre- and Postchallenge1.51 ratio (unitless)Standard Deviation 0.23
Exclusive Smokers Pre-challengeChanges in Heart Rate Variability Standing Ratio Pre- and Postchallenge1.38 ratio (unitless)Standard Deviation 0.21
Exclusive Smokers After Smoking ChallengeChanges in Heart Rate Variability Standing Ratio Pre- and Postchallenge1.34 ratio (unitless)Standard Deviation 0.23
Comparison: Linear mixed models adjusted for age, sex, race/ethnicity compared the within-and between-group responses following product usep-value: 0.182Mixed Models Analysis
p-value: 0.0795% CI: [-0.09, 0.004]Mixed Models Analysis
p-value: 0.19695% CI: [-0.09, 0.02]Mixed Models Analysis
p-value: 0.69Mixed Models Analysis
Primary

Changes in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challenge

Expressed as a percentage of beats (supine recordings had be 5 minutes or longer to be valid). We used the SphygmoCor system for these recordings (Atcor medical). Participants attended V2 1-2 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability was recorded supine for 10 minutes or more, pre and post smoking/vaping challenge. For controls is was repeated after a 10-minute break.

Time frame: During V2 (scheduled up to 4 weeks from enrollment) and obtained after 10 minutes of supine rest, before and after smoking/vaping challenge

Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw. Some participants pre or post challenge due to poor ECG signals (noise) or frequent premature ventricular contractions did not have a usable 10 minute recording

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersChanges in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challenge33.64 percent of sequential intervalsStandard Deviation 20.83
Exclusive E-Cig UsersChanges in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challenge36.46 percent of sequential intervalsStandard Deviation 21.96
Never UsersChanges in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challenge34.82 percent of sequential intervalsStandard Deviation 21.85
Exclusive E-cigarette Users Post-challengeChanges in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challenge31.02 percent of sequential intervalsStandard Deviation 22.9
Exclusive Smokers Pre-challengeChanges in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challenge18.46 percent of sequential intervalsStandard Deviation 19.72
Exclusive Smokers After Smoking ChallengeChanges in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challenge15.45 percent of sequential intervalsStandard Deviation 18.61
Comparison: Linear mixed models adjusted for age, sex, race/ethnicity compared the within-and between-group responses following product usep-value: <0.001Mixed Models Analysis
Comparison: Fixed effects from mixed models of measures before and after nicotine-containing product challenge (covariate-adjusted)p-value: <0.00195% CI: [-9.89, -3.2]Mixed Models Analysis
p-value: 0.00195% CI: [-9.71, -2.52]Mixed Models Analysis
p-value: 0.787Mixed Models Analysis
Primary

Changes in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challenge

Participants attended Visit 2 (1-4 weeks after enrollment visit). They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.

Time frame: Spirometry performed pre-challenge and within 15 minutes post-challenge (up to 4 weeks from enrollment)

Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw. Some spirometry recordings were of poor quality and upon review by pulmonologist they were deemed not usable.

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersChanges in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challenge86.91 predicted percentileStandard Deviation 27.33
Exclusive E-Cig UsersChanges in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challenge85.17 predicted percentileStandard Deviation 25.68
Never UsersChanges in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challenge87.94 predicted percentileStandard Deviation 23.45
Exclusive E-cigarette Users Post-challengeChanges in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challenge80.20 predicted percentileStandard Deviation 23.35
Exclusive Smokers Pre-challengeChanges in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challenge71.09 predicted percentileStandard Deviation 31.09
Exclusive Smokers After Smoking ChallengeChanges in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challenge68.49 predicted percentileStandard Deviation 27.12
Comparison: Linear mixed models adjusted for age, sex, race/ethnicity compared the within-and between-group responses following product usep-value: 0.014Mixed Models Analysis
Comparison: Fixed effects from mixed models of measures before and after nicotine-containing product challenge (covariate-adjusted)p-value: 0.01695% CI: [-9.21, -0.95]Mixed Models Analysis
p-value: 0.99895% CI: [-4.47, 4.48]Mixed Models Analysis
p-value: 0.013Mixed Models Analysis
Primary

Changes in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challenge

maximum amount of air that the subject can forcibly expel during the first second following maximal inhalation, expressed as a percentage of the predicted normal values in the population. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.

Time frame: before and after smoking/vaping challenge during Visit 2 (1-4 weeks after enrollment visit)

Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw. Some spirometry recordings were of poor quality and upon review by pulmonologist they were deemed not usable.

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersChanges in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challenge92.00 predicted percentage of populationStandard Deviation 13.41
Exclusive E-Cig UsersChanges in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challenge91.12 predicted percentage of populationStandard Deviation 14.13
Never UsersChanges in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challenge93.83 predicted percentage of populationStandard Deviation 13.32
Exclusive E-cigarette Users Post-challengeChanges in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challenge89.76 predicted percentage of populationStandard Deviation 15.63
Exclusive Smokers Pre-challengeChanges in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challenge82.91 predicted percentage of populationStandard Deviation 18.9
Exclusive Smokers After Smoking ChallengeChanges in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challenge80.43 predicted percentage of populationStandard Deviation 18.25
Comparison: Linear mixed models adjusted for age, sex, race/ethnicity compared the within-and between-group responses following product use.p-value: 0.017Mixed Models Analysis
p-value: 0.00595% CI: [-5.18, -0.91]Mixed Models Analysis
p-value: 0.27495% CI: [-3.61, 1.03]Mixed Models Analysis
p-value: 0.098Mixed Models Analysis
Primary

Changes in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challenge

The post challenge spirometry was recorded \<15 minutes post end of exposure. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.

Time frame: before and after smoking/vaping challenge during Visit 2 (1-4 weeks after enrollment visit)

Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw. Some spirometry recordings were of poor quality and upon review by pulmonologist they were deemed not usable.

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersChanges in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challenge95.74 ratio (unitless)Standard Deviation 9.63
Exclusive E-Cig UsersChanges in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challenge95.93 ratio (unitless)Standard Deviation 8.28
Never UsersChanges in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challenge95.66 ratio (unitless)Standard Deviation 8.9
Exclusive E-cigarette Users Post-challengeChanges in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challenge92.23 ratio (unitless)Standard Deviation 11.67
Exclusive Smokers Pre-challengeChanges in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challenge91.18 ratio (unitless)Standard Deviation 12.56
Exclusive Smokers After Smoking ChallengeChanges in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challenge90.89 ratio (unitless)Standard Deviation 11.12
Comparison: Linear mixed models adjusted for age, sex, race/ethnicity compared the within-and between-group responses following product use.p-value: 0.001Mixed Models Analysis
p-value: 0.00195% CI: [-5.43, -1.35]Mixed Models Analysis
p-value: 0.77895% CI: [-2.53, 1.89]Mixed Models Analysis
p-value: 0.002Mixed Models Analysis
Primary

Changes in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challenge

Participants attended V2 up to 4 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability was recorded supine for 10 minutes or more, pre and post smoking/vaping challenge. For controls it was repeated after a 10 minute break.

Time frame: heart rate variability recordings of at least 10 minutes per-challenge and 15 minutes post-challenge (up to 4 weeks from enrollment)

Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw. Some participants pre or post challenge due to poor ECG signals (noise) or frequent premature ventricular contractions did not have a usable 10 minute recording

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersChanges in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challenge66.44 millisecondsStandard Deviation 34.49
Exclusive E-Cig UsersChanges in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challenge71.10 millisecondsStandard Deviation 38.78
Never UsersChanges in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challenge71.20 millisecondsStandard Deviation 44.42
Exclusive E-cigarette Users Post-challengeChanges in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challenge64.40 millisecondsStandard Deviation 46.33
Exclusive Smokers Pre-challengeChanges in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challenge48.29 millisecondsStandard Deviation 35.01
Exclusive Smokers After Smoking ChallengeChanges in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challenge44.44 millisecondsStandard Deviation 38.73
Comparison: Linear mixed models adjusted for age, sex, race/ethnicity compared the within-and between-group responses following product use Outcome measure ln transformed for analysis.p-value: 0.001Mixed Models Analysis
Comparison: Fixed effects from mixed models of measures before and after nicotine-containing product challenge (covariate-adjusted)p-value: 0.00195% CI: [-0.31, -0.08]Mixed Models Analysis
p-value: 0.00195% CI: [-0.33, -0.09]Mixed Models Analysis
p-value: 0.847Mixed Models Analysis
Primary

Changes in Systolic Blood Pressure Pre- and Post-challenge.

Visit 2 was scheduled up to 4 weeks from enrollment visit, fasting.. They came in the morning after 8 hours of fasting and refraining from nicotine products. Systolic blood pressure (left brachial artery using an oscillometric method) was measured supine, after 10 minutes rest (Pre) and repeated after they underwent smoking or vaping changes. The post challenge blood pressures were recorded 15-20 minutes post end of exposure. For controls, all measurements were repeated in the same order after a 10 minute break.

Time frame: During Visit 2 (1 - 4 weeks post enrollment) before and after smoking/vaping challenge and for controls after a 10 minute break

Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw.

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersChanges in Systolic Blood Pressure Pre- and Post-challenge.118.4 mmHgStandard Deviation 11.72
Exclusive E-Cig UsersChanges in Systolic Blood Pressure Pre- and Post-challenge.120.25 mmHgStandard Deviation 12
Never UsersChanges in Systolic Blood Pressure Pre- and Post-challenge.119.74 mmHgStandard Deviation 11.21
Exclusive E-cigarette Users Post-challengeChanges in Systolic Blood Pressure Pre- and Post-challenge.125.40 mmHgStandard Deviation 11.54
Exclusive Smokers Pre-challengeChanges in Systolic Blood Pressure Pre- and Post-challenge.126.43 mmHgStandard Deviation 16.72
Exclusive Smokers After Smoking ChallengeChanges in Systolic Blood Pressure Pre- and Post-challenge.132.00 mmHgStandard Deviation 16.09
Comparison: Linear mixed models adjusted for age, sex, race/ethnicity compared the within-and between-group responses following product usep-value: 0.002Mixed Models Analysis
Comparison: Fixed effects from mixed models of measures before and after nicotine-containing product challenge (covariate-adjusted)p-value: 0.00195% CI: [1.36, 5.24]Mixed Models Analysis
p-value: 0.00295% CI: [1.2, 5.38]Mixed Models Analysis
p-value: 0.992ANCOVA
Primary

Forced Expiratory Volume (FEV1)- Pre Challenge

FEV1 is a primary measure of pulmonary disease obtained by spirometry that will be assessed before and after an acute exposure challenge. These are per-challenge values

Time frame: V2 up to 4 weeks from enrollment visit , fasting, pre challenge session

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersForced Expiratory Volume (FEV1)- Pre Challenge82.9 percentage of volume exhaledStandard Deviation 18.9
Exclusive E-Cig UsersForced Expiratory Volume (FEV1)- Pre Challenge93.8 percentage of volume exhaledStandard Deviation 13.3
Never UsersForced Expiratory Volume (FEV1)- Pre Challenge92.0 percentage of volume exhaledStandard Deviation 13.4
p-value: 0.001ANCOVA
Comparison: these are pairwise follow-up tests probing a larger omnibus group difference involving three groups.p-value: 0.82295% CI: [-4.08, 3.24]ANCOVA post-hoc pairwise group compariso
Comparison: these are pairwise follow-up tests probing a larger omnibus group difference involving three groups.p-value: 0.00195% CI: [2.974, 11.559]ANCOVA post-hoc pairwise group compariso
Comparison: These are pairwise follow-up tests probing a larger omnibus group difference involving three groups.p-value: <0.00195% CI: [3.485, 11.889]ANCOVA post-hoc pairwise group compariso
Secondary

60 Seconds Heart Rate Recovery (Beats Per Minute)

Difference in heart rate 60 seconds post treadmill minus maximal heart rate during treadmill..

Time frame: During V2 (1-4 weeks after enrollment visit) the treadmill stress test was done last, following Nicotine-containing product challenge (users) or pretend 10 minute exposure for controls

ArmMeasureValue (MEAN)Dispersion
Exclusive Smokers60 Seconds Heart Rate Recovery (Beats Per Minute)19.62 beats per minute (bpm)Standard Deviation 10.38
Exclusive E-Cig Users60 Seconds Heart Rate Recovery (Beats Per Minute)26.74 beats per minute (bpm)Standard Deviation 9.06
Never Users60 Seconds Heart Rate Recovery (Beats Per Minute)28.06 beats per minute (bpm)Standard Deviation 8.26
p-value: <0.001ANCOVA
Secondary

Arterial Pulse Wave Analysis (PWA), Augmentation Index (at 75 Bpm, %)

Analysis of radial pressure wave forms allows for non-invasive estimation of central aortic pressures, accounting for pressure amplification and the amplitude of the arterial pulse wave as it moves through arteries away from the heart. The Atcor Sphygmacor system can derive central aortic pressures from radial tracings using a validated transfer function. This computation is performed using the pulse wave analysis (PWA) mode. Pulse Wave Analysis via radial tonometry was obtained as a measure of chronic exposure.

Time frame: v2 was generally 1-2 weeks after enrollment visit, with a window up to 4 weeks from V1

ArmMeasureValue (MEDIAN)
Exclusive SmokersArterial Pulse Wave Analysis (PWA), Augmentation Index (at 75 Bpm, %)19.5 percentage of central pulse pressure
Exclusive E-Cig UsersArterial Pulse Wave Analysis (PWA), Augmentation Index (at 75 Bpm, %)0.50 percentage of central pulse pressure
Never UsersArterial Pulse Wave Analysis (PWA), Augmentation Index (at 75 Bpm, %)1.00 percentage of central pulse pressure
p-value: <0.001ANCOVA
Comparison: Never Users minus Exclusive E-Cig Usersp-value: 0.00395% CI: [-6.019, -1.245]ANCOVA post-hoc pairwise group compariso
Comparison: Never Users minus Exclusive Smokersp-value: <0.00195% CI: [-11.14, -5.62]ANCOVA post-hoc pairwise group compariso
Comparison: Exclusive E-Cig Users minus Exclusive Smokersp-value: 0.00195% CI: [-7.456, -2.04]ANCOVA post-hoc pairwise group compariso
Secondary

Autonomic Measures - RMSSD

Root mean square of standard deviation of rr intervals. Obtained fasting and refraining from nicotine exposure using the Sphymocor system. We used 10 or more minutes of supine data to derive heart rate variability measures.

Time frame: v2 was generally 1-2 weeks after enrollment visit, with a window up to 4 weeks from V1

ArmMeasureValue (MEDIAN)
Exclusive SmokersAutonomic Measures - RMSSD43.6 ms
Exclusive E-Cig UsersAutonomic Measures - RMSSD63.3 ms
Never UsersAutonomic Measures - RMSSD58.3 ms
p-value: 0.15ANCOVA
Secondary

Diastolic Blood Pressure (DBP)

During V2, Diastolic Blood Pressure was measured using the oscillometric technique before an acute exposure challenge following a standardized protocol. After resting supine for 10 minutes blood pressure was measured on both arms and the average of the last two values was used. Participants attended v2 in the morning, fasting and refraining from nicotine products for at least 8 hours.

Time frame: V2 was generally 1-2 weeks after enrollment with a window up to 4 weeks from V1, recorded after resting supine for 10 minutes

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersDiastolic Blood Pressure (DBP)76.6 mmHgStandard Deviation 10.7
Exclusive E-Cig UsersDiastolic Blood Pressure (DBP)71.1 mmHgStandard Deviation 7.5
Never UsersDiastolic Blood Pressure (DBP)70.4 mmHgStandard Deviation 7.1
p-value: 0.199ANCOVA
Secondary

Exercise Treadmill Stress Test (ETT)-Peak METS

An ETT to determine exercise capacity will be completed as a measure of chronic exposure. Peak metabolic equivalents (METs, 1 MET=3.5 ml O2 uptake/kg body weight/minute) were determined at all exercise stages, peak exercise, and 1-minute post-exercise.

Time frame: Treadmill test done only once at the end of v2 after completion of all other post-challenge assessment tests. V2 was scheduled 1-4 weeks from enrollment vist

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersExercise Treadmill Stress Test (ETT)-Peak METS8.39 METSStandard Deviation 3.19
Exclusive E-Cig UsersExercise Treadmill Stress Test (ETT)-Peak METS10.29 METSStandard Deviation 2.01
Never UsersExercise Treadmill Stress Test (ETT)-Peak METS11.06 METSStandard Deviation 2.42
p-value: <0.001ANCOVA
Comparison: Never Users minus Exclusive E-Cig Usersp-value: <0.00195% CI: [0.733, 1.824]ANCOVA post-hoc pairwise group compariso
Comparison: Never Users minus Exclusive Smokersp-value: <0.00195% CI: [1.083, 2.395]ANCOVA post-hoc pairwise group compariso
Comparison: Exclusive E-Cig Users minus Exclusive Smokersp-value: 0.16595% CI: [-0.19, 1.11]ANCOVA post-hoc pairwise group compariso
Secondary

Forced Vital Capacity (FVC)

Forced Vital Capacity is a measure of how much air can be exhaled forcefully obtained by spirometry pre acute exposure challenge.

Time frame: recordings obtained during V2 in the morning, fasting and refraining from nicotine for at least 8 hours. This visit was generally 1-2 weeks after enrollment date with a window up to 4 weeks

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersForced Vital Capacity (FVC)90.3 Percent predicted FVCStandard Deviation 16
Exclusive E-Cig UsersForced Vital Capacity (FVC)98.3 Percent predicted FVCStandard Deviation 13.5
Never UsersForced Vital Capacity (FVC)96.5 Percent predicted FVCStandard Deviation 15.1
p-value: 0.022ANCOVA
Comparison: Never Users minus Exclusive E-Cig Usersp-value: 0.952ANCOVA post-hoc pairwise group compariso
Comparison: post hoc pairwise group comparisons.. Never Users minus Exclusive Smokersp-value: 0.014ANCOVA post-hoc pairwise group compariso
Comparison: Exclusive E-Cig Users minus Exclusive Smokersp-value: 0.011ANCOVA post-hoc pairwise group compariso
Secondary

Fractional Exhaled Nitric Oxide (FeNO)

Fractional Exhaled Nitric Oxide is a measure of airway inflammation measured before an acute exposure challenge.

Time frame: recordings obtained during V2 in the morning, fasting and refraining from nicotine for at least 8 hours. This visit was generally 1-2 weeks after enrollment date with a window up to 4 weeks

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersFractional Exhaled Nitric Oxide (FeNO)9.7 ppbStandard Deviation 12.3
Exclusive E-Cig UsersFractional Exhaled Nitric Oxide (FeNO)14.5 ppbStandard Deviation 14.7
Never UsersFractional Exhaled Nitric Oxide (FeNO)16.2 ppbStandard Deviation 11
p-value: <0.001ANCOVA
Comparison: Never Users minus Exclusive E-Cig Users:p-value: 0.01395% CI: [0.039, 0.322]ANCOVA post-hoc pairwise group compariso
Comparison: Never Users minus Exclusive Smokersp-value: <0.00195% CI: [0.514, 0.844]ANCOVA post-hoc pairwise group compariso
Comparison: Exclusive E-Cig users minus Exclusive Smokersp-value: <0.00195% CI: [0.336, 0.66]ANCOVA post-hoc pairwise group compariso
Secondary

Heart Rate (HR)

Heart Rate pre-acute exposure challenge was obtained after resting supine for 10 minutes during V2 in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior.

Time frame: Participants attended V2 generally 1-4 weeks after enrollment with a window that allowed up to 4 weeks after enrollment

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersHeart Rate (HR)65.3 beats/minuteStandard Deviation 11.7
Exclusive E-Cig UsersHeart Rate (HR)58.3 beats/minuteStandard Deviation 9.2
Never UsersHeart Rate (HR)59.6 beats/minuteStandard Deviation 8.2
p-value: <0.001ANCOVA
Comparison: Never Users minus Exclusive E-Cig Usersp-value: 0.26995% CI: [-1.048, 3.752]ANCOVA post-hoc pairwise group compariso
Comparison: Never Users minus Exclusive Smokersp-value: <0.00195% CI: [-8.37, -2.78]ANCOVA post-hoc pairwise group compariso
Comparison: Exclusive E-Cig Users minus Exclusive Smokersp-value: <0.00195% CI: [-9.672, -4.183]ANCOVA post-hoc pairwise group compariso
Secondary

Heart Rate Reserve (%)

Measure of maximal exercise capacity adjusted for age, calculated as max heart rate during treadmill divided by (220 minus the participant's age in yrs)

Time frame: During V2 (1-4 weeks after enrollment visit) the treadmill stress test was done last, following Nicotine-containing product challenge (users) or 10 minute pretend exposure for never-users

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersHeart Rate Reserve (%)83.25 percentage of heart rate reserveStandard Deviation 11.58
Exclusive E-Cig UsersHeart Rate Reserve (%)87.89 percentage of heart rate reserveStandard Deviation 8.81
Never UsersHeart Rate Reserve (%)91.72 percentage of heart rate reserveStandard Deviation 7.58
p-value: <0.001ANCOVA
Comparison: Never Users minus Exclusive E-Cig Usersp-value: <0.00195% CI: [0.733, 1.824]ANCOVA post-hoc pairwise group compariso
Comparison: Never Users minus Exclusive Smokersp-value: <0.00195% CI: [1.083, 2.395]ANCOVA post-hoc pairwise group compariso
Comparison: Exclusive E-Cig Users minus Exclusive Smokersp-value: 0.16595% CI: [-0.19, 1.11]ANCOVA post-hoc pairwise group compariso
Secondary

Heart Rate Variability (HRV) - Pre Product Use Challenge

Heart Rate Variability PNN50(%) measured before an exposure challenge. Participants attended visit 2 fasting and refraining from nicotine for at least 8 hours.

Time frame: V2 two was generally scheduled 1-4 weeks after enrollment visit with a window up to 4 weeks. HRV measures obtained after resting supine for 10 minutes

Population: heart rate variability depends on a good quality electrocardiogram, and some participants due to noise, significant pauses, very slow heart rate or frequent premature ventricular contractions did not have usable records, hence lower number analyzed.

ArmMeasureValue (MEDIAN)
Exclusive SmokersHeart Rate Variability (HRV) - Pre Product Use Challenge11.4 percentage of intervals
Exclusive E-Cig UsersHeart Rate Variability (HRV) - Pre Product Use Challenge37.1 percentage of intervals
Never UsersHeart Rate Variability (HRV) - Pre Product Use Challenge31.0 percentage of intervals
p-value: 0.035ANCOVA
Secondary

Peak Rate Pressure Product (RPP, Peak Heart Rate Multiplied by Peak Systolic Blood Pressure)

Peak RPP was calculated by multiplying maximun heart rate during exercise by systolic blood pressure as a reliable assessment of cardiac workload

Time frame: During V2 (1-4 weeks after enrollment visit) the treadmill stress test was done last, following Nicotine-containing product challenge (users) or pretend 10 minute exposure for controls

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersPeak Rate Pressure Product (RPP, Peak Heart Rate Multiplied by Peak Systolic Blood Pressure)249.99 mmHg x bpmStandard Deviation 62.82
Exclusive E-Cig UsersPeak Rate Pressure Product (RPP, Peak Heart Rate Multiplied by Peak Systolic Blood Pressure)284.76 mmHg x bpmStandard Deviation 51.36
Never UsersPeak Rate Pressure Product (RPP, Peak Heart Rate Multiplied by Peak Systolic Blood Pressure)290.86 mmHg x bpmStandard Deviation 48.61
p-value: <0.001ANCOVA
Comparison: Never Users minus Exclusive E-Cig usersp-value: <0.00195% CI: [0.733, 1.824]ANCOVA post-hoc pairwise group compariso
Comparison: Never Users minus Exclusive Smokersp-value: <0.00195% CI: [1.083, 2.395]ANCOVA post-hoc pairwise group compariso
Comparison: Exclusive E-Cig Users minus Exclusive Smokersp-value: 0.16595% CI: [-0.19, 1.11]ANCOVA post-hoc pairwise group compariso
Secondary

Systolic Blood Pressure (BP)

Blood Pressure measured using the oscillometric technique before an acute exposure challenge following standardized protocol. After resting supine for 10 minutes blood pressure was measured on both arms and the average of the last two values was used.

Time frame: V2 was up to 4 weeks from enrollment visit, after resting supine for 10 minutes

ArmMeasureValue (MEAN)Dispersion
Exclusive SmokersSystolic Blood Pressure (BP)126.4 mmHgStandard Deviation 16.7
Exclusive E-Cig UsersSystolic Blood Pressure (BP)119.7 mmHgStandard Deviation 11.2
Never UsersSystolic Blood Pressure (BP)118.4 mmHgStandard Deviation 11.7
p-value: 0.549ANCOVA

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026